Savara Inc. Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>Savara Inc. invites stockholders to its 2024 Annual Meeting on June 6, 2024, highlighting progress in aPAP trials, diagnostics, and financing.</b>

AI Summary

Savara Inc (SVRA) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Savara Inc. will hold its 2024 Annual Meeting of Stockholders on June 6, 2024, at 3:00 p.m. ET via live webcast. The company made progress with its Phase 3 IMPALA-2 trial for autoimmune pulmonary alveolar proteinosis (aPAP) and the molgramostim development program. Savara launched aPAP ClearPath™, a diagnostic blood test, and a disease state awareness campaign for aPAP. The company strengthened its management team and was added to the Russell 3000® and Nasdaq Biotechnology Indices. Savara completed an $80M equity financing and believes it is capitalized into 2026.

Why It Matters

For investors and stakeholders tracking Savara Inc, this filing contains several important signals. The meeting will cover key strategic decisions and provide an update on the company's progress, including pivotal trial results and financial outlook. Shareholder approval is likely required for matters such as the election of directors and executive compensation, impacting the company's governance and future direction.

Risk Assessment

Risk Level: low — Savara Inc shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate negative financial or operational news, indicating a low-risk filing.

Analyst Insight

Stockholders should review the proxy materials to understand proposed board members, executive compensation, and vote on key company matters.

Key Numbers

• 2024 — Annual Meeting Year (2024 Annual Meeting of Stockholders)
• June 6 — Annual Meeting Date (Annual Meeting date)
• 3:00 p.m. ET — Annual Meeting Time (Annual Meeting time)
• 2Q 2024 — Anticipated Results Date (Anticipate top line results from the IMPALA-2 trial at the end of 2Q 2024)
• $80M — Equity Financing Amount (completed an $80M equity financing)
• 2026 — Capitalization Horizon (sufficiently capitalized into 2026)

Key Players & Entities

• Savara Inc. (company) — Registrant
• June 6, 2024 (date) — Annual Meeting date
• 3:00 p.m. Eastern Time (time) — Annual Meeting time
• www.virtualshareholdermeeting.com/SVRA2024 (url) — Annual Meeting webcast link
• IMPALA-2 (trial) — Phase 3 trial
• autoimmune pulmonary alveolar proteinosis (aPAP) (disease) — condition being treated
• molgramostim (drug) — investigational therapy
• $80M (dollar_amount) — equity financing

FAQ

Risk Factors

• Regulatory Approvals [medium — regulatory]: The development and commercialization of molgramostim are subject to extensive regulatory review and approval processes by health authorities.
• Market Acceptance [medium — market]: The success of molgramostim depends on market acceptance by physicians and patients, and competition from existing or alternative therapies.
• Financing Needs [medium — financial]: The company's ability to fund its operations and development programs, including the $80M equity financing, is critical for future success.
• Clinical Trial Success [high — operational]: The outcome of the IMPALA-2 Phase 3 trial is crucial for the potential approval and commercialization of molgramostim.

Key Financial Figures

• $80M — ology Indices. Finally, we completed an $80M equity financing and, under the current
• $20,000 — es, which we do not expect would exceed $20,000 and would reimburse the firm for its re

Filing Documents

• d785934ddef14a.htm (DEF 14A) — 607KB
• g785934g07g07.jpg (GRAPHIC) — 213KB
• g785934g08g08.jpg (GRAPHIC) — 181KB
• g785934g25o54.jpg (GRAPHIC) — 67KB
• g785934g41g41.jpg (GRAPHIC) — 71KB
• 0001193125-24-118077.txt (&nbsp;) — 1343KB

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 21 Certain Relationships and Related Transactions 24 Equity Compensation Plan Information 25 Compensation Discussion and Analysis 26

Executive Compensation Tables

Executive Compensation Tables 33 Director Compensation 42 Audit Committee Report 44 Principal Accountant Fees and Services 45 Proposal 1 Election of Directors 46 Proposal 2 Approval of the Savara Inc. 2024 Omnibus Incentive Plan 47 Proposal 3 Approval of an amendment to our Amended and Restated Certificate of Incorporation 53 Proposal 4 Ratification of Independent Registered Public Accounting Firm 55 Proposal 5 Advisory Vote on the Compensation of our Named Executive Officers 56 Other Matters 57 Stockholder Proposals and Director Nominations for 2025 Annual Meeting 57 Appendix A: 2024 Omnibus Incentive Plan A-1 Appendix B: Certificate of Amendment to the Amended and Restated Certificate of Incorporation B-1 -i- Table of Contents SAVARA INC. One Summit Square 1717 Langhorne Newtown Rd. Suite 300 Langhorne, PA 19047 PROXY STATEMENT 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held on June 6, 2024 GENERAL INFORMATION ABOUT THE MEETING Savara Inc., a Delaware corporation (Savara, we, us, our, the company, the Company or our company), is making proxy materials, including this proxy statement, available to our stockholders via the internet in connection with the solicitation of proxies by the Savara Board of Directors (the Board of Directors or Board) for use at our 2024 Annual Meeting of Stockholders to be held virtually on June 6, 2024 at 3:00 p.m. Eastern Time via live webcast at www.virtualshareholdermeeting.com/SVRA2024, and at any adjournment or postponement thereof (the Annual Meeting). This proxy statement, the attached notice of the Annual Meeting, a proxy card and our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 are collectively referred to as the proxy materials. The proxy materials are first being made available to our stockholders on or about April 26, 2024. Notice of Internet Availability of Proxy Materials All stockholders have the ability to access the prox

View Full Filing

View this DEF 14A filing on SEC EDGAR